Member Info for flyingmachine

Thanks Gusto, took them a while to post up. Very telling in the Covid-19 test comparison slide, but won't mention any names. They took thoes names out in the PDF deck.

Sure Dave, I don't mind that. Just for fun then, £5 wager from me that FDA lands before WHO approval. Could be close run thing actually....

Sorry Dave, I don't give specific predictions on SP but you'll know I am very positive about the upward trajectory of SP from here. It has a way to go, that's for sure.....

Dave, FDA approval is running in parallel to WHO approval, both submitted after CE Marking achieved on 22nd May. I expect FDA approval to arrive first, normally 3.5 - 5 weeks after submission, dependent on how busy FDA are. So latest normal expectation for FDA approval for me is by the end of next week.

....in case anyone still hasn't read the latest summary of Genedrive that was posted yesterday, here it is again at the start of this thread. We are good to go Houston, products ready, all systems check, T-10 and counting......

For those that are new to GDR or haven't paid full attention the past few days....

Take a look at the latest Genedrive Investor presentation....
http://www.genedriveplc.com/company-reports/InvestorPresentationJune2020.pdf
Just taking a few key points from that: the top tier GDR PCR test USPs stand out amongst the competition, the 100 country distribution channels available, the Covid-19 CE Mark plus other approvals applied for (FDA and WHO), the AIHL GDR product would bring estimated revenue of between £40m-£65m ongoing per year (on its own this would justify more than the current Mcap), tests supplied to the USA DoD is expected to bring in multi-millions ongoing, then finally DB expressed ""faith and confidence of significant orders and commercial contracts".

Add to that the Global Health Fund investment in GDR, that the Lions Head Global Partners are the fund manager for GHIF, the LHGP relationship with DIVOC Health in India, DIVOC Health application for approval for GDR test in India = massive sales in India to come very shortly!! That is in now way diminishing Genedrive's own sales and marketing efforts (hence FDA and WHO approvals applied for).

Then consider the timing of the bond conversion by GHIF.....just before the influx of significant news flow for approvals and sales. Good timing from an investment point of view by GHIF and they know alot more than we do about what is coming,

All pointing in a positive direction in the not too distant future, latest in next two weeks in my view.

Lastly, Covid-19 is not disappearing any time soon, testing will still be so important for the foreseeable future, even more so to control the virus as countries try to release their economies out of lockdown.

Punit! That's a great and succinct summary from joining up all the dots that have been laid out today. I agree!

marve, I see the timing of the bonds conversion as being significant - execute conversion just before significant positive new flow. I believe GHIF know more than us (with their links with LHGP for example) about what is on the immediate horizon. They benefit in two ways - their investment has an impact and they achieve investment success......

"Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries."

"Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success."

To be clear, this is in addition to the efforts that Genedrive and their current (or future) distributors are putting in to make sales in Europe (CE Marked product), USA (FDA EUA applied for), continental Africa and Asian markets (WHO EUA approval applied for).

So, Covid-19 test sales is not just India, but India will be significant from my understanding.

Not forgetting AIHL and other existing Genedrive products. AIHL on its own is estimated would produce a global revenue stream of £40m-£65m per year.

http://www.genedriveplc.com/company-reports/InvestorPresentationJune2020.pdf

I have picked up a couple of significant pieces of information which some investors may already be aware of, take it as you will, this has not come from Genedrive.....

- focusing our efforts on getting India going. Every country wants tests to be done and to work through new protocols etc which take time.
- Dr Kahol is well plugged into the Delhi medical scene
- thinking about options in Africa.....
- and other nations eg Ukraine and Ecuador.
- to be frank in India alone we could both ensure a very significant cashflow for Genedrive, but also the biggest impact.
- to be frank in India alone we could both ensure a very significant cashflow for Genedrive, but also the biggest impact.

I repeated the last point twice, just so you didn't miss it.

strongboes, the timing of the conversion into shares is also interesting....just before the influx of significant news flow for approvals and sales. Good timing from an investment point of view by GHIF and they know alot more than we do about what is coming, I am sure of that.

Exactly Pilgrim, the links are clear as day.....

Look, there has not been any further cash injection into GDR - this is a bond conversion. In fact, GDR have paid the bond holders "£685,000 in cash reflecting the balance of accrued interest owed, in full satisfaction of the obligations of the Company under the convertible bond. "

After the conversion GDR " expects to have gross cash balances of approximately £8.6 million". That's mainly funds from the previous placement.

Please read the RNS....."genedrive expects to have gross cash balances of approximately £8.6 million".

The RNS is hugely positive.....GHIF investment in GDR, LHGP fund manager for GHIF, LHGP relationship with DIVOC Health in India, DIVOC Health getting approval for GDR test in India = massive sales in India to come very shortly!!

This also ties up with Lions Head Global Partners link to DIVOC Health in India.....see my earlier post.

JAdam, you are wrong and not seeing the links in the chain....

"Furthermore, Lion’s Head Global Partners is fund manager to the Global Health Investment Fund (GHIF), a Gates Foundation sponsored, healthcare focused investment vehicle. GHIF’s purpose is to fund late stage trials for the commercialization of, and interventions related to, drugs developed to combat diseases that predominantly afflict third-world countries."

Statement from Christopher Egerton-Warburton, co-CEO of LHGP in relation to DIVOC Health in India.....

"yes this is group we are associated with to bring the Genedrive test to India".

No doubt we will be selling tests in India, lots of them.

Among his closing comments, DB expressed......"faith and confidence of significant orders and commercial contracts"....

It is coming.....

David Budd's Genedrive presenattion from last Friday. Go through it, the outlook is fantastic.......

http://www.genedriveplc.com/company-reports/InvestorPresentationJune2020.pdf

It does make you wonder why a concerted pullback of Covid stocks just when the main indices are starting to factor in large drops because of the continued spread of Covid across the world, including the real threat of 2nd waves, then the impact of that on economies. There's also been a load of de-ramping across all Covid boards over past couple of days so perhaps the shorters are getting desparate, doing all they can to drive SPs down when they know the tide is already turning against their favour.